Swedish clinical-stage biotech Anocca AB has secured approximately SEK 440 million ($46 million) in financing to advance its pipeline of T-cell immunotherapies, including its lead candidate VIDAR-1, a gene-edited TCR-T therapy targeting mutant KRAS in pancreatic cancer.

The funding round was led by Mellby Gård, with continued backing from AMF, Ramsbury, and other existing shareholders, alongside participation from new investors. According to Anocca, the additional capital will support the ongoing early-stage clinical development of VIDAR-1 and enable progress on its preclinical programs.

Recruitment is currently open for Phase 1 of the multi-centre trial of VIDAR-1, which is being conducted at leading university hospitals across Sweden, Denmark, Germany, and The Netherlands.

Reagan Jarvis, co-founder and CEO of Anocca, said: “We thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic. The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need.”

Johan Andersson, chairman of Mellby Gård, added: “We have been invested in Anocca throughout its preclinical development and are pleased to see the Company transition into a clinical stage biotech. We look forward to seeing Anocca help patients that have limited treatment options today with their innovative approach to T-cell therapies.”

The company said its proprietary platform and manufacturing capabilities provide a foundation for developing next-generation TCR-T cell therapies designed to address solid tumors driven by specific oncogenic mutations, including KRAS, which is a key driver of pancreatic and other cancers with poor prognosis.

SEB Corporate Finance acted as financial advisor on the transaction, while Mannheimer Swartling and HWF Advokater provided legal counsel.